Header Logo

Connection

AARON THRIFT to Male

Back to Details
This is a "connection" page, showing publications AARON THRIFT has written about Male.
AARON THRIFT
Connection Strength
2.173
Male
  1. Trends and Variations in Pancreatic Cancer Mortality Among US Metro and Nonmetro Adults, 1999-2020. J Clin Gastroenterol. 2024 Jul 01; 58(6):627-631.
    View in: PubMed
    Score: 0.036
  2. Patient- and system-level factors associated with racial/ethnic disparities in the delivery of guideline-concordant therapy among US?patients with gastric cancer. J Surg Oncol. 2024 Jun; 129(8):1542-1553.
    View in: PubMed
    Score: 0.036
  3. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
    View in: PubMed
    Score: 0.036
  4. An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients. Dig Dis Sci. 2024 Jul; 69(7):2430-2436.
    View in: PubMed
    Score: 0.035
  5. Somatic mutations of esophageal adenocarcinoma: a comparison between Black and White patients. Sci Rep. 2024 04 18; 14(1):8988.
    View in: PubMed
    Score: 0.035
  6. Recent Trends in the Incidence of Gastric Cancer in the United States. J Clin Gastroenterol. 2024 01 01; 58(1):39-45.
    View in: PubMed
    Score: 0.035
  7. Disparities in cancer mortality patterns: A comprehensive examination of U.S. rural and urban adults, 1999-2020. Cancer Med. 2023 Sep; 12(18):18988-18998.
    View in: PubMed
    Score: 0.034
  8. Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
    View in: PubMed
    Score: 0.033
  9. Preventable causes of cancer in Texas by race/ethnicity: Major modifiable risk factors in the population. PLoS One. 2022; 17(10):e0274905.
    View in: PubMed
    Score: 0.032
  10. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer. 2022 Sep; 173:250-262.
    View in: PubMed
    Score: 0.031
  11. The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting. Clin Gastroenterol Hepatol. 2023 05; 21(5):1252-1260.e5.
    View in: PubMed
    Score: 0.031
  12. Missed Opportunities for Screening or Surveillance Among Patients with Newly Diagnosed Non-cardia Gastric Adenocarcinoma. Dig Dis Sci. 2023 03; 68(3):761-769.
    View in: PubMed
    Score: 0.031
  13. Admixture Mapping in African Americans Identifies New Risk Loci for HCV-Related Cirrhosis. Clin Gastroenterol Hepatol. 2023 04; 21(4):1023-1030.e39.
    View in: PubMed
    Score: 0.031
  14. Risk Score Using Demographic and Clinical Risk Factors Predicts Gastric Intestinal Metaplasia Risk in a U.S. Population. Dig Dis Sci. 2022 09; 67(9):4500-4508.
    View in: PubMed
    Score: 0.030
  15. Alcohol consumption and the risk of gastric intestinal metaplasia in a U.S. Veterans population. PLoS One. 2021; 16(11):e0260019.
    View in: PubMed
    Score: 0.030
  16. Preventable causes of cancer in Texas by race/ethnicity: tobacco smoking. Epidemiol Health. 2021; 43:e2021046.
    View in: PubMed
    Score: 0.029
  17. Gastric Cancer Epidemiology. Gastrointest Endosc Clin N Am. 2021 Jul; 31(3):425-439.
    View in: PubMed
    Score: 0.029
  18. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018. PLoS One. 2021; 16(6):e0252164.
    View in: PubMed
    Score: 0.029
  19. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control. 2021 Apr; 32(4):317-325.
    View in: PubMed
    Score: 0.028
  20. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance. Gastrointest Endosc Clin N Am. 2021 Jan; 31(1):1-26.
    View in: PubMed
    Score: 0.028
  21. Racial/Ethnic Differences in Cancers Attributable to Preventable Infectious Agents in Texas, 2015. Public Health Rep. 2020 Nov/Dec; 135(6):805-812.
    View in: PubMed
    Score: 0.028
  22. External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population. Dig Dis Sci. 2021 07; 66(7):2387-2393.
    View in: PubMed
    Score: 0.027
  23. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies? Dig Dis Sci. 2021 06; 66(6):1965-1973.
    View in: PubMed
    Score: 0.027
  24. Dietary Factors and Gastric Intestinal Metaplasia Risk Among US Veterans. Dig Dis Sci. 2021 05; 66(5):1600-1610.
    View in: PubMed
    Score: 0.027
  25. Melanoma Incidence Among Non-Hispanic Whites in All 50 US States From 2001 Through 2015. J Natl Cancer Inst. 2020 05 01; 112(5):533-539.
    View in: PubMed
    Score: 0.027
  26. Demographic and Lifestyle Risk Factors for Gastric Intestinal Metaplasia Among US Veterans. Am J Gastroenterol. 2020 03; 115(3):381-387.
    View in: PubMed
    Score: 0.027
  27. Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Dig Dis Sci. 2020 09; 65(9):2691-2699.
    View in: PubMed
    Score: 0.026
  28. Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Age-Period-Cohort Analysis. Cancer Epidemiol Biomarkers Prev. 2020 01; 29(1):88-94.
    View in: PubMed
    Score: 0.026
  29. Preventable causes of cancer in Texas by race/ethnicity: Alcohol consumption. Alcohol. 2020 06; 85:21-26.
    View in: PubMed
    Score: 0.026
  30. Risk and Predictors of Esophageal and Stomach Cancers in HIV-Infected Veterans: A Matched Cohort Study. J Acquir Immune Defic Syndr. 2019 07 01; 81(3):e65-e72.
    View in: PubMed
    Score: 0.025
  31. Factors associated with favorable survival outcomes for Asians with hepatocellular carcinoma: A sequential matching cohort study. PLoS One. 2019; 14(4):e0214721.
    View in: PubMed
    Score: 0.025
  32. Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clin Gastroenterol Hepatol. 2019 09; 17(10):2117-2125.e3.
    View in: PubMed
    Score: 0.025
  33. Ancestry and Risk of Hepatic Fibrosis and Inflammation in Patients With HCV Infection. Clin Gastroenterol Hepatol. 2019 08; 17(9):1912-1914.
    View in: PubMed
    Score: 0.024
  34. Editorial: less acid, less cancer? Is this the question? Authors' reply. Aliment Pharmacol Ther. 2018 10; 48(8):878-879.
    View in: PubMed
    Score: 0.024
  35. Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. Dig Dis Sci. 2018 11; 63(11):3112-3119.
    View in: PubMed
    Score: 0.024
  36. Underuse of Surgery Accounts for Racial Disparities in Esophageal Cancer Survival Times: A Matched Cohort Study. Clin Gastroenterol Hepatol. 2019 03; 17(4):657-665.e13.
    View in: PubMed
    Score: 0.024
  37. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018 08; 48(4):469-477.
    View in: PubMed
    Score: 0.024
  38. The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. Am J Gastroenterol. 2018 09; 113(9):1310.
    View in: PubMed
    Score: 0.024
  39. Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation. Clin Gastroenterol Hepatol. 2019 01; 17(1):65-72.e5.
    View in: PubMed
    Score: 0.024
  40. Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol. 2018 08; 113(8):1148-1155.
    View in: PubMed
    Score: 0.024
  41. Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. Clin Gastroenterol Hepatol. 2018 10; 16(10):1598-1606.e4.
    View in: PubMed
    Score: 0.023
  42. Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic?Variants. Gastroenterology. 2018 04; 154(5):1273-1281.e3.
    View in: PubMed
    Score: 0.023
  43. Alcohol, smoking and risk of oesophago-gastric cancer. Best Pract Res Clin Gastroenterol. 2017 Oct; 31(5):509-517.
    View in: PubMed
    Score: 0.022
  44. Obesity and Risk of Nonalcoholic Fatty Liver Disease: A Comparison of Bioelectrical Impedance Analysis and Conventionally-Derived Anthropometric Measures. Clin Gastroenterol Hepatol. 2017 12; 15(12):1965-1967.
    View in: PubMed
    Score: 0.022
  45. External Validation of the Michigan Barrett's Esophagus Prediction Tool. Clin Gastroenterol Hepatol. 2017 07; 15(7):1124-1126.
    View in: PubMed
    Score: 0.022
  46. Rising Incidence of Colorectal Cancer Among Young Hispanics in Texas. J Clin Gastroenterol. 2017 01; 51(1):34-42.
    View in: PubMed
    Score: 0.021
  47. Risk Profiles for Barrett's Esophagus Differ between New and Prevalent, and Long- and Short-Segment Cases. PLoS One. 2016; 11(12):e0169250.
    View in: PubMed
    Score: 0.021
  48. Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. Dig Dis Sci. 2017 02; 62(2):526-533.
    View in: PubMed
    Score: 0.021
  49. Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2017 02; 15(2):310-312.
    View in: PubMed
    Score: 0.021
  50. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol. 2016 11; 111(11):1528-1535.
    View in: PubMed
    Score: 0.021
  51. Inverse Association Between Gluteofemoral Obesity and Risk of?Barrett's Esophagus in a Pooled Analysis. Clin Gastroenterol Hepatol. 2016 10; 14(10):1412-1419.e3.
    View in: PubMed
    Score: 0.020
  52. Coffee or Tea, Hot or Cold, Are Not Associated With Risk of Barrett's Esophagus. Clin Gastroenterol Hepatol. 2016 May; 14(5):769-72.
    View in: PubMed
    Score: 0.020
  53. Premature Birth and Large for Gestational Age Are Associated with Risk of Barrett's Esophagus in Adults. Dig Dis Sci. 2016 Apr; 61(4):1139-47.
    View in: PubMed
    Score: 0.020
  54. Unravelling the Riddle of Gastroesophageal Reflux Disease, Obesity, and Barrett's Esophagus. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2273-5.
    View in: PubMed
    Score: 0.019
  55. Mendelian randomization study of height and risk of colorectal cancer. Int J Epidemiol. 2015 Apr; 44(2):662-72.
    View in: PubMed
    Score: 0.019
  56. Mendelian Randomization Study of Body Mass Index and Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2015 Jul; 24(7):1024-31.
    View in: PubMed
    Score: 0.019
  57. Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2225-32.
    View in: PubMed
    Score: 0.019
  58. Metabolic syndrome and the risk of Barrett's oesophagus in white males. Aliment Pharmacol Ther. 2015 Jun; 41(11):1182-9.
    View in: PubMed
    Score: 0.019
  59. Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: a Mendelian randomization study. J Natl Cancer Inst. 2014 Nov; 106(11).
    View in: PubMed
    Score: 0.018
  60. Alcohol and the risk of Barrett's esophagus: a pooled analysis from the International BEACON Consortium. Am J Gastroenterol. 2014 Oct; 109(10):1586-94.
    View in: PubMed
    Score: 0.018
  61. Effects of physical activity on melatonin levels in previously sedentary men and women. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1696-9.
    View in: PubMed
    Score: 0.018
  62. Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. J Clin Gastroenterol. 2014 Mar; 48(3):218-23.
    View in: PubMed
    Score: 0.018
  63. Risk of esophageal adenocarcinoma decreases with height, based on consortium analysis and confirmed by Mendelian randomization. Clin Gastroenterol Hepatol. 2014 Oct; 12(10):1667-76.e1.
    View in: PubMed
    Score: 0.017
  64. A multibiomarker risk score helps predict risk for Barrett's esophagus. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1267-71.
    View in: PubMed
    Score: 0.017
  65. No significant effects of smoking or alcohol consumption on risk of Barrett's esophagus. Dig Dis Sci. 2014 Jan; 59(1):108-16.
    View in: PubMed
    Score: 0.017
  66. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol. 2013 Jun; 108(6):915-22.
    View in: PubMed
    Score: 0.016
  67. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013 Feb; 11(2):138-44.e2.
    View in: PubMed
    Score: 0.016
  68. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012 Dec; 23(12):3155-3162.
    View in: PubMed
    Score: 0.016
  69. A clinical risk prediction model for Barrett esophagus. Cancer Prev Res (Phila). 2012 Sep; 5(9):1115-23.
    View in: PubMed
    Score: 0.016
  70. The influence of prediagnostic demographic and lifestyle factors on esophageal squamous cell carcinoma survival. Int J Cancer. 2012 Sep 01; 131(5):E759-68.
    View in: PubMed
    Score: 0.015
  71. Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. Cancer Causes Control. 2012 Apr; 23(4):555-64.
    View in: PubMed
    Score: 0.015
  72. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Aliment Pharmacol Ther. 2011 Nov; 34(10):1235-44.
    View in: PubMed
    Score: 0.015
  73. Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study. Int J Cancer. 2012 May 15; 130(10):2407-16.
    View in: PubMed
    Score: 0.015
  74. Lifetime alcohol consumption and risk of Barrett's Esophagus. Am J Gastroenterol. 2011 Jul; 106(7):1220-30.
    View in: PubMed
    Score: 0.014
  75. HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort. J Hepatol. 2026 Mar; 84(3):578-586.
    View in: PubMed
    Score: 0.010
  76. Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits. Int J Cancer. 2026 Mar 01; 158(5):1193-1203.
    View in: PubMed
    Score: 0.010
  77. Comparing the performance of 3 sarcopenia definitions for predicting adverse events prior to liver transplant. Hepatol Commun. 2025 Jun 01; 9(6).
    View in: PubMed
    Score: 0.010
  78. A Simple, Interpretable Machine Learning Model Based on Clinical Factors Accurately Predicts Incident Dysplasia or Malignancy in Barrett's Esophagus. Dig Dis Sci. 2025 Aug; 70(8):2739-2749.
    View in: PubMed
    Score: 0.009
  79. Myosteatosis Is Associated With Frailty and Poor Physical Function in Patients Undergoing Liver Transplant Evaluation: A Cohort Study. Clin Transplant. 2024 Dec; 38(12):e70034.
    View in: PubMed
    Score: 0.009
  80. Neighborhood-level deprivation mediates racial and ethnic disparities in HCC diagnosis in Texas. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.009
  81. Baylor College of Medicine (BCM) model predicts recurrence after mucosectomy of colorectal lateral spreading tumors in European cohorts. Clin Res Hepatol Gastroenterol. 2024 10; 48(8):102460.
    View in: PubMed
    Score: 0.009
  82. Race/ethnicity and sex differences in the association between area-level arsenic exposure concentration and hepatocellular carcinoma (HCC) incidence rates in Texas. An ecological study. Environ Res. 2024 Jan 01; 240(Pt 2):117538.
    View in: PubMed
    Score: 0.009
  83. A Study of Dietary Patterns Derived by Cluster Analysis and Their Association With Metabolic Dysfunction-Associated Steatotic Liver Disease Severity Among Hispanic Patients. Am J Gastroenterol. 2024 03 01; 119(3):505-511.
    View in: PubMed
    Score: 0.008
  84. Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.008
  85. Association of Diet Quality with Metabolic (Dysfunction) Associated Fatty Liver Disease in Veterans in Primary Care. Nutrients. 2023 Jun 01; 15(11).
    View in: PubMed
    Score: 0.008
  86. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
    View in: PubMed
    Score: 0.008
  87. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
    View in: PubMed
    Score: 0.008
  88. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. JAMA Netw Open. 2022 10 03; 5(10):e2234221.
    View in: PubMed
    Score: 0.008
  89. Reduced frequency of high cholesterol levels among patients with intracerebral haemorrhage. J Clin Neurosci. 2002 Jul; 9(4):376-80.
    View in: PubMed
    Score: 0.008
  90. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. 2022 09; 163(3):649-658.e2.
    View in: PubMed
    Score: 0.008
  91. Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. Sci Rep. 2022 04 05; 12(1):5695.
    View in: PubMed
    Score: 0.008
  92. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2022 02; 76(2):294-301.
    View in: PubMed
    Score: 0.007
  93. International Trends in Esophageal Squamous Cell Carcinoma and Adenocarcinoma Incidence. Am J Gastroenterol. 2021 05 01; 116(5):1072-1076.
    View in: PubMed
    Score: 0.007
  94. Sex Differences in the Risk of Barrett's Esophagus Associated With the Metabolic Effects of Obesity. J Clin Gastroenterol. 2020 10; 54(9):795-800.
    View in: PubMed
    Score: 0.007
  95. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
    View in: PubMed
    Score: 0.007
  96. Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology. 2020 12; 159(6):2065-2076.e1.
    View in: PubMed
    Score: 0.007
  97. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021 01; 19(1):61-71.e15.
    View in: PubMed
    Score: 0.007
  98. Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. Dig Dis Sci. 2021 03; 66(3):912-916.
    View in: PubMed
    Score: 0.007
  99. Risk Prediction Models for Barrett's Esophagus Discriminate Well and Are Generalizable in an External Validation Study. Dig Dis Sci. 2020 10; 65(10):2992-2999.
    View in: PubMed
    Score: 0.007
  100. Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System. Clin Colorectal Cancer. 2020 06; 19(2):e49-e57.
    View in: PubMed
    Score: 0.007
  101. Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):427-433.
    View in: PubMed
    Score: 0.007
  102. Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. Clin Gastroenterol Hepatol. 2020 11; 18(12):2701-2709.e3.
    View in: PubMed
    Score: 0.007
  103. Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population. Dig Dis Sci. 2020 08; 65(8):2403-2411.
    View in: PubMed
    Score: 0.007
  104. Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium. Cancer. 2019 12 01; 125(23):4210-4223.
    View in: PubMed
    Score: 0.006
  105. Incidence of AIDS-Related Kaposi Sarcoma in All 50 United States From 2000 to 2014. J Acquir Immune Defic Syndr. 2019 08 01; 81(4):387-394.
    View in: PubMed
    Score: 0.006
  106. Statin use and risk of liver cancer: Evidence from two population-based studies. Int J Cancer. 2020 03 01; 146(5):1250-1260.
    View in: PubMed
    Score: 0.006
  107. Validation of HIV-infected cohort identification using automated clinical data in the Department of Veterans Affairs. HIV Med. 2019 09; 20(8):567-570.
    View in: PubMed
    Score: 0.006
  108. External validation of a model to determine risk of progression of Barrett's oesophagus to neoplasia. Aliment Pharmacol Ther. 2019 05; 49(10):1274-1281.
    View in: PubMed
    Score: 0.006
  109. No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. Clin Gastroenterol Hepatol. 2019 10; 17(11):2227-2235.e1.
    View in: PubMed
    Score: 0.006
  110. Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma. Dig Dis Sci. 2019 02; 64(2):367-372.
    View in: PubMed
    Score: 0.006
  111. Changing Trends in Colorectal Cancers (Detected by Screening, During Screening Intervals, or Associated With Nonadherence) Identify Possible Health Care System Quality Measures. Gastroenterology. 2019 02; 156(3):809-811.
    View in: PubMed
    Score: 0.006
  112. Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors. Gastroenterology. 2019 01; 156(1):43-45.
    View in: PubMed
    Score: 0.006
  113. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
    View in: PubMed
    Score: 0.006
  114. Long-term follow up of patients with obscure gastrointestinal bleeding examined with video capsule endoscopy. Medicine (Baltimore). 2018 Jul; 97(29):e11429.
    View in: PubMed
    Score: 0.006
  115. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. Aliment Pharmacol Ther. 2018 07; 48(1):55-64.
    View in: PubMed
    Score: 0.006
  116. Lorenz Curves and Gini Coefficient Analyses Indicate Inefficiencies in Esophageal Adenocarcinoma Screening. Clin Gastroenterol Hepatol. 2019 02; 17(3):560-562.e2.
    View in: PubMed
    Score: 0.006
  117. Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus. Gastroenterology. 2018 08; 155(2):316-326.e6.
    View in: PubMed
    Score: 0.006
  118. Model for Identifying Individuals at Risk for Esophageal Adenocarcinoma. Clin Gastroenterol Hepatol. 2018 08; 16(8):1229-1236.e4.
    View in: PubMed
    Score: 0.006
  119. Factors That Contribute to Indeterminate Results From the?QuantiFERON-TB Gold In-Tube Test in Patients With?Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018 10; 16(10):1616-1621.e1.
    View in: PubMed
    Score: 0.006
  120. Impact of cap-assisted colonoscopy on the learning curve and quality in colonoscopy: a randomized controlled trial. Gastrointest Endosc. 2018 Mar; 87(3):723-732.e3.
    View in: PubMed
    Score: 0.006
  121. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol. 2017 Jul; 112(7):1049-1055.
    View in: PubMed
    Score: 0.005
  122. Clinical Manifestations of Helicobacter pylori-Negative Gastritis. Clin Gastroenterol Hepatol. 2017 Jul; 15(7):1037-1046.e3.
    View in: PubMed
    Score: 0.005
  123. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017 03; 152(4):812-820.e5.
    View in: PubMed
    Score: 0.005
  124. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017 02; 66(2):355-362.
    View in: PubMed
    Score: 0.005
  125. Prevalence of Celiac Disease Among Unsuspected Patients Presenting to Open Access Endoscopy. Clin Gastroenterol Hepatol. 2017 01; 15(1):137-139.
    View in: PubMed
    Score: 0.005
  126. Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Gut. 2017 10; 66(10):1739-1747.
    View in: PubMed
    Score: 0.005
  127. Common variants in the obesity-associated genes FTO and MC4R are not associated with risk of colorectal cancer. Cancer Epidemiol. 2016 10; 44:1-4.
    View in: PubMed
    Score: 0.005
  128. A Model to Predict the Risk of Keratinocyte Carcinomas. J Invest Dermatol. 2016 06; 136(6):1247-1254.
    View in: PubMed
    Score: 0.005
  129. Symptoms of Obstructive Sleep Apnea, Gastroesophageal Reflux and the Risk of Barrett's Esophagus in a Population-Based Case-Control Study. PLoS One. 2015; 10(6):e0129836.
    View in: PubMed
    Score: 0.005
  130. Risk factors for Barrett's esophagus compared between African Americans and non-Hispanic Whites. Am J Gastroenterol. 2014 Dec; 109(12):1870-80.
    View in: PubMed
    Score: 0.005
  131. Five-year longitudinal assessment of the downstream impact on schistosomiasis transmission following closure of the Three Gorges Dam. PLoS Negl Trop Dis. 2012; 6(4):e1588.
    View in: PubMed
    Score: 0.004
  132. A 5-year longitudinal study of schistosomiasis transmission in Shian village, the Anning River Valley, Sichuan Province, the Peoples' Republic of China. Parasit Vectors. 2011 Mar 24; 4:43.
    View in: PubMed
    Score: 0.004
  133. Screen time and metabolic risk factors among adolescents. Arch Pediatr Adolesc Med. 2010 Jul; 164(7):643-9.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.